Back to top
more

Teleflex (TFX)

(Delayed Data from NYSE)

$239.18 USD

239.18
210,668

-0.36 (-0.15%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $239.20 +0.02 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Teleflex (TFX) Real-World Data Outcome Supports UroLift System

Teleflex's (TFX) new real-world data outcomes together with product launches demonstrate the importance of UroLift System for most BPH patients.

Teleflex (TFX) Rides on UroLift Growth, Hurt by Pandemic Woes

Teleflex (TFX) has decided to increase its investment in 2021 and run a national campaign for the full year.

Teleflex (TFX) Q2 Earnings Surpass Estimates, Margins Up

Teleflex (TFX) reports better-than-expected revenues with strong segmental and geographical performance driving the top line in second-quarter 2021.

Teleflex (TFX) Q2 Earnings and Revenues Top Estimates

Teleflex (TFX) delivered earnings and revenue surprises of 17.13% and 4.79%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Teleflex (TFX) Earnings Expected to Grow: Should You Buy?

Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Teleflex (TFX) Moves 3.8% Higher: Will This Strength Last?

Teleflex (TFX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Here's Why You Should Add Teleflex (TFX) to Your Portfolio

Strong segmental performance in America and Asia is driving the top line for Teleflex (TFX).

Globus Medical (GMED) Marks New Milestone for ExcelsiusGPS

Globus Medical's (GMED) ExcelsiusGPS Robotic Navigation system reaches new surgical milestone for spinal procedures.

National Vision (EYE) Banks on Partnerships Amid COVID-19 Woes

National Vision (EYE) is confident about its financial flexibility and liquidity helping it to navigate this pandemic.

Fresenius Medical's (FMS) Xenios Gets NMPA Nod for ECMO System

Fresenius Medical (FMS) company receives expedited approval from NMPA permitting the Xenios AG's console and patient kits for ECMO therapy in China.

Hologic (HOLX) COVID Test With Saliva Sample Gets CE Mark

Per Hologic (HOLX), saliva collection is noninvasive and painless. The availability of this alternative specimen type should facilitate screening at schools, workplaces and other settings.

Orthofix's (OFIX) SpinalStim Demonstrates Improved Fusion Rates

Orthofix's (OFIX) SpinalStim bone growth device demonstrates impressive fusion rates for patients recovering from lumbar fusion surgery.

Omnicell (OMCL)-Chartwell Partner to Implement IVX Workflow

Omnicell (OMCL) and Chartwell partner to implement Omnicell's IVX Workflow for the management of chemotherapy drug product preparations.

Masimo (MASI) Reports Study Findings Backing the SedLine

Masimo (MASI) releases new study findings assessing two parameters provided by the SedLine that exhibit high predictability for mortality 180 days after cardiac arrest.

Orthofix (OFIX) Launches FORZA Ti PLIF Spacer System in the US

Orthofix (OFIX) launches FORZA Ti PLIF Spacer System to improve posterior lumbar interbody fusion procedures in the United States.

Teleflex (TFX) Procedure Volume Recovers as Pandemic Subsides

The UroLift System remains a major contributor to Teleflex (TFX) revenues.

TeleFlex (TFX) Urolift Grows, Organic Sales Hit by Pandemic

On the strength of a successful 2020 campaign, Teleflex (TFX) doubles the awareness for UroLift in the targeted population of men with BPH.

Teleflex (TFX) Beats on Q1 Earnings and Revenues, Raises View

The acquisition of Z-Medica and an increase in sales of new products contribute to Teleflex's (TFX) revenue growth in Americas in Q1

Teleflex (TFX) Q1 Earnings and Revenues Top Estimates

Teleflex (TFX) delivered earnings and revenue surprises of 17.62% and 2.04%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Teleflex (TFX) to Report a Decline in Earnings: What to Look Out for

Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Teleflex (TFX) Up 2.6% Since Last Earnings Report?

Teleflex (TFX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Teleflex (TFX) Beats on Q4 Earnings and Revenues, Margins Fall

Teleflex (TFX) witnesses significant sequential improvement in segmental performance during the fourth quarter on gradual recovery of the economy.

Teleflex (TFX) Beats Q4 Earnings and Revenue Estimates

Teleflex (TFX) delivered earnings and revenue surprises of 7.26% and 3.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Teleflex (TFX) Q4 Earnings Expected to Decline

Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TeleFlex (TFX) Organic Sales Hit by COVID-19, Urolift Grows

TeleFlex (TFX) Interventional business revenues are down due to the cancellation of certain non-emergent procedures.